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ABSTRACT  
     Glutamatergic system stimulationthe nucleus accumbens shell, may affect anxiety-related behaviors, 
aversive learning and memory. Glutamate receptors are differentially distributed in pre- and postsynaptic 
sites contributing to neuronal communications.The present study aimed to examine the possible involvement 
of the NAc shell presynaptic NMDA receptors on NMDA induced responses, using the elevated-plus maze 
(EPM) task in maleWistar rats. Bilateral guide cannulae were implanted to allow microinjection of 
glutamatergic agonist (NMDA) or ca
+2
 channel blocker (SKF96365 hydrochloride) agents. Pretest intra-NAc 
shell infusion of NMDA induced anxiolytic-like behaviors and impaired the EPM-associated memory upon 
test and retest, respectively. In addition our findings showed that, the intra-NAc shell infusion of Ca
+2
 
channel blocker at applied doses, does not alter the anxiety-like response and aversive memory upon test and 
retest, respectively. Furthermore, infusing the subthreshold dose SKF prior to the injection of effective doses 
of NMDA, reduced the anxiolytic-like response and improved the aversive memory impairment which had 
already been induced by intra-NAc shell NMDA injection. Our study showed that,inhibition of the 
neurotransmitter exocytosis from pre-synaptic neuron via Ca
+2
 channel blockade bySKF96365 decreases 
affected induced by NMDA in the NAc shell region, indicating the involvement of the pre-synaptic NMDA 
receptors in NMDA induced responses.Therefore, NMDA's ability to increase anxiolytic-like behaviors and 
the aversive memory impairment may be the result of an action on pre-synaptic glutamatergic receptors 
which in turn decrease the glutamate effect at synaptic terminal level. 
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INTRODUCTION 
     Glutamate is one of the main excitatory 
neurotransmitters in central nervous system [1] 
which is involved in many cognitive and non-
cognitiveprocesses including learning and 
memory as well as thepathogenesis of anxiety-
related disorders, fear conditioning [2-
7].Glutamate exerts its actions via two different 
receptor types: ionotropic receptors and 
metabotropic. NMDA receptor (as an ionotropic 
glutamate receptor) plays a critical role in the 
regulation of glutamate-induced behaviors such 
as learning and memory formation [4, 5] and 
anxiety-related behaviors [2, 8]. Both 
ionotropicand metabotropicreceptors are 
differentially distributed in pre-and postsynaptic 
sites contributing to neuronal communications 
and signal processing which underlie 
functionssuch as learning and memory formation 
[9, 10].NMDA is shown to exert its effect via 
pre- and postsynaptic receptors[11, 12].The 
presynaptic effect is mediated either directly by 
NMDA receptors localized on axons or synaptic 
buttons or indirectly through postsynaptic 
receptors which release retrograde messengers 
that act on presynaptic elements[12-14]. The 
postsynaptic effect is mediated either by the 
synaptic NMDA receptors localized on dendritic 
spines orextra-synaptic receptors localized on 
dendritic shafts and the soma [15]. Furthermore, 
some of investigations have postulated that, the 
postsynaptic release of glutamate activates the 
presynaptic NMDA receptors hence 
regulatedifferentforms of different forms of 











release of neurotransmitters. Neuromodulation 
affects the ability of voltage-gated Ca
+2
channels 
to open, close, or inactivate in response to 
membrane depolarization and alters their 
response to repetitive stimuli in an activity-
dependent manner[17]. 
Thenucleus accumbens(a major component of 
the ventral striatum) is a structure located in the 
rostrobasal forebrain andcomposed ofthe core 
and shell parts[18]. The NAc shell is strongly 
suggested to be a pivotal brain site for 
modulation of emotion, motor activity [19], 
motivation-related learning, memory[20, 21]and 
anxiety [22-24].Evidence has shown that, NAc 
NMDARs are involved in novel 
physiologicaland pathophysiological 
emotionalresponses [25].More 
recentinvestigations have suggested 
thatNMDARs may also present atthe presynaptic 
axonal terminals and potentially affectthe 
presynaptic neurotransmitter release[12, 21, 26-
32]. 
Emotional states (including, fear and 
aversion)can be modulated, by enhancing or 
impairing, memory formation[33]. Due to 
possible misinterpretations, the available animal 
models for learning and memory seem to have a 
limited ability to detect the effectof drugs on 
anxiety and fear [34]. Therefore, the proposed 
test-retest paradigm in the elevated plus-
maze(EPM) task is an attempt to concomitantly 
assess the effects of drugs on anxiety, learning 
and memory in Rat.The present study aimed to 
examine the possible involvement of the NAc 
shell presynaptic NMDA receptors onNMDA 
induced responses, using the elevated-plus maze 
(EPM) task in adult Wistar rats. 
 
MATERIALS AND METHODS 
Animals 
     Male Wistar rats (Institute of cognitive science; 
Tehran, Iran) weighting 250 – 280 g at the time of 
surgery were used. The animals were housed in 
colony, maintained at (22  2 C) a 12-h light/12-h 
dark cycle (lights on at 07:00 h) and allowed free 
access to food and water within standard 
polypropylene cages. The animals were permitted 
to adapt to the laboratory condition for at least 1 
week prior to surgery. Eight animals were 
considered in each experimental group. The 
experiments were carried out during the light phase 
of the cycle. 
Drugs 
Ketamine and xylazine (Alfasan Chemical Co, 
Woerden, Holland) were used for animal 
anesthesia.N-methyl-D-Aspartate (NMDA) 
receptor agonist and SKF96365 
hydrochloride(SKF, ca
+2
 channel blocker) were 
used for microinjections prior to the behavioral 
tests.All drugs were dissolved in sterile 0.9% 
saline, just before the experiment. NMDA and 
SKFwere administered into the NAcshell at a 
volume of 0.3µl in each side.Control animals 
received saline. 
 
Surgical procedure and microinjections 
Animals were anesthetized intraperitoneally using 
ketamine hydrochloride (50 mg/kg) and xylazine (4 
mg/kg) then placed in a Stoelting stereotaxic 
instrument (Wood Dale, IL, USA).A stainless steel 
guide cannula (22 gauge) was implanted in the 
right and left NAc shell regions according to the 
atlas of Paxinos and Watson [35]. The stereotaxic 
coordinates for the NAc regions were as follows: 
+1.4 mm posterior to bregma, ±0.8 mm lateral to 
the midline, and− 5.5mm ventral to the dorsal 
surface of the skull. The cannulae were fixed to the 
skull using acrylic dental cement. Rats were 
allowed 5 days before the test to recover from 
surgery. The left and right NAc were infused by 
means of an internal cannula (27 gauge), 
terminating 2 mm below the tip of the guides, 
connected by polyethylene tubing to a 2µl 
Hamilton syringe (Bonaduz, GR, Switzerland). A 
volume of 0.3µl solution was injected over a 60-
second period, in each side. The inner cannulae 
were left in place for an additional 60 seconds to 
allow diffusion of the solution and to reduce the 
possibility of reflux. Intra-NAc shell injections 
were made just five minutes before testing. 
Apparatus 
We used a wooden elevated plus-maze (EPM) 
apparatusconsisting of two oppositely positioned 
open- arms (50×10 cm) and two enclosed arms 
(50×10×40 cm),surrounded by1cm high Plexiglas 
ledgeso thatto prevent falls set up 50 cm above the 
floor. The junction area of the four arms (central 
platform) measured10×10 cm[36-38]. 
 
 





Rats were placed in the experimental room at least 
1h before testing. All experiments were done 
during the light phase of the L/D cycle between 11 
a.m. and 2 p.m. Animals’ behaviors were tracked 
and recorded by an observer who quietly sat 1m 
behind one of the closed arms of the maze, using a 
chronometer. Five minutes post- drug treatment, 
rats were individually placed at the center of the 
plus maze, facing one of the open arms and 
allowed for 5 min free exploration in EPM (test 
session) after which were taken back to their home 
cages. In 24 hours, rats were returned to the test 
room and placed again in the EPM for a new 
exploration period of 5 min (retest session). The 
observer measured: 1- time spent in open arms, 2- 
time spent in closed arms, 3-number of entries into 
open arms and 4- number of entries into closed 
arms during the 5minute period both upon test and 
retest. An entry was defined as ‘all four paws in the 
arm’. In between EPM sessions and after each rat, 
the maze was cleaned with distilled water. The 
obtained data were used to calculate: a- % OAT 
(the ratio of time spent in open arms to the time 
spend in all arms ×100); b-%OAE (the ratio of 
entries into open arms to total entries×100) [39-41] 
and c- the total closed and open arm entries were 
considered as a relatively pure index for the 
locomotor activity [42, 43]. 
 
Experimental design 
Experiment1: the effects ofintra- NAc shell 
pretest microinjections of NMDA,SKF,SKFprior 
to NMDA on open-arms exploratory behaviors 
To substantiate whether the intra- NAc shell 
microinjection of drugsinvolved in anxiety, drug 
infusion were given before EPM testing. In this 
experiment11groups of animals were examined.  
These were as follow: 1- animals which received 
intra-NAc shell saline (0.3µl/rat) or NMDA (0.125, 
0.25, and 0.5µg/rat), 5 min after saline (0.3µl/rat); 
2- animals which received intra-NAc shell saline 
(0.3µl/rat) or SKF (0.0625, 0.0125, 0.25 and 0. 
5µg/rat), 5 min before saline (0.3µl/rat) and 3- 
animals which received intra-NAc shell saline 
(0.3µl/rat) or the subthreshold dose SKF 
(0.0125µg/rat), 5 min before different doses of 
NMDA (0.25 and 0.5µg/rat).To investigate the 
possible drugs carryover effects of aversive 
learning during test day to aversive memory upon 
retest, treated groups were retested in the EPM 24 
h later, undrugged. 
Statistical analysis 
Data were expressed as mean±S.E.M and analyzed 
using the repeated measure protocol during test and 
retest days. In addition to the analysis made to 
compare test to test or retest to retest, the two-way 
analysis of variance (ANOVA) was also applied. 
Where F-value was significant, one-way ANOVA 
and post-hoc analysis (Tukey-test) was performed. 
Between-groups differences with P<0.05, were 
considered statistically significant. 
 
RESULTS  
The experiment results: 
The effects of pretestintra-NAc shell 
microinjection of NMDA on open-arms 
exploratory-like behaviors 
     Repeated measure and Post hoc analyses 
demonstrated that, NMDA increases the %OAT (at 
0.5μg/rat, Fig.1; panel 1A), %OAE (at 0.25 and 
0.5μg/rat, Fig.1; panel 1B) while decreases the 
locomotor activity (at 0.25 and 0.5μg/rat, Fig.2; 
panel 1C) upon test, indicating an anxiolytic-like 
response to NMDA. 
Adding to the above, data showed that NMDA 
increases the %OAT (at 0.5μg/rat, Fig.1; panel 2A) 
while does not alter %OAE (Fig.1; panel 2B) and 
the locomotor activity (Fig.1; panel 2C) upon retest 
as compared to the control group, indicating an 
impairment of the aversive memory acquisition by 
NMDA. On the other hand, this intervention 
decreased the %OAE on retest day (Fig.1, panel 
2B) as compared to same groups on test day (Fig.1, 
panel 1B).  
According to the above data, NMDA induced 
anxiolytic-like behavior. Furthermore, the retest 
data suggest that the NMDA anxiolytic-like effect 
may also be linked to the impairment in further 
avoidance acquisition. The corresponding repeated 
measure results have been demonstrated in table 1. 
 




Table1: repeated measure and two ANOVA results with P values for experiments 
 
The effects of pretest intra-NAc shell 
microinjection of SKF on open-arms 
exploratory-like behaviors 
Repeated measure and post hoc analyses revealed 
that, SKF does not alter %OAT (Fig.1; panel 3A), 
%OAE (Fig.1; panel 3B) while decreases the 
locomotor activity (at 0.125 and 0.25μg/rat, Fig.1; 
panel 3C) upon test as compared to the control 
group, indicating that SKF does not appear to 
alter anxiety-like behaviors in the EPM task. 
Based on our data, SKF elicited no effect on the 
%OAT (Fig.1; panel 4A), %OAE (Fig.1; panel 
4B) while decreases the locomotor activity(at 
0.255μg/rat, Fig.1; panel 4CB) upon retest as 
compared to control group.  
To conclude, while SKF did not seem to alter the 
anxiety-like behavior compared to control groups 
on test day, it improved the aversive memory on 
retest day as compared to the same groups on test 
day. This experiment repeated measure results are 
demonstrated in table 1. 
 
The effects of pretestintra-NAc shell 
microinjection of SKF prior to NMDA on open-
arms exploratory-like behaviors 
According to the two-way ANOVA and post hoc 
analyses, intra-NAc shell microinjection of SKF 
prior to NMDA causes a significant decrease in 
the %OAT (at 0.25 and 0.5μg/rat, Fig.1; panel 
5A), %OAE (at 0.25 and 0.5μg/rat, Fig.1; panel 
5B) while does not significantly affect the 
locomotor activity on test day (Fig.1; panel 5C) as 
compared to the NMDA-treated groups on test 
day (Fig.1; panel 1A, 1B and 1C). These data 
indicated that, the intra-NAc shell microinjection 
of the subthreshold dose of SKF may potentially 
reverse the NMDA-induced anxiolytic-like 
response.  
Moreover, the above experiment led to significant 
decrease in %OAT (at 0.5μg/rat, Fig.1; panel 6A), 
without altering the %OAE (Fig.1; panel 6B) and 
locomotor activity (fig.1; panel 6C) on retest day 
as compared to NMDA-treated groups during the 
same day (Fig.1; panel 1A, 1B and 1C). These 
data indicated that, intra-NAc shell microinjection 
of the subthreshold dose SKF reverses the 
NMDA-induced aversive memory acquisition 
impairment. 
Given the above data, the subthreshold dose SKF 
seems to decrease the NMDA-induced anxiolytic-
like behaviors and the aversive memory 
acquisition impairment on test and retest days. 
This experiment ANOVA results are summarized 
in table 1.  
 
 
Experiments Behaviors Day Group Day and Group 
interaction 
Final results conclusion 
for each experiment 





Repeated measure analysis 
results for NMDA 
microinjection into NAc 
(Panel 1 and 2 of fig.1) 
%OAT 0.006 0.939 8.495 0.000 0.887 0.482 
%OAE 12.800 0.001 10.617 0.000 5.972 0.000 
Locomotion 4.143 0.049 2.245 0.084 0.309 0.870 
Repeated measure analysis 
results for SKF 
microinjection into NAc 
(Panel 3 and 4 of fig.1) 
 F(1,28) P F(3,28) P F(3,28) P SKFinto NAc shell did 
not alter anxiolytic-like 
behavior and aversive 
memory acquisition 
%OAT 5.672 0.024 1.775 0.175 1.027 0.396 
%OAE 5.612 0.025 1.651 0.200 1.127 0.355 
Locomotion 2.594 0.119 11.397 0.000 2.225 0.107 
Two ANVA results 
between(panel5 and 1of fig. 
1) 





induced by NMDA into 
NAc shell 
%OAT 35.996 0.000 5.723 0.006 4.172 0.022 
%OAE 25.408 0.000 11.925 0.000 1.261 0.294 
Locomotion 0.022 0.883 1.711 0.193 14.319 0.000 
TwoANOVA results 
between 
  ( panel 6 and 2 of fig. 1) 
 F(1,48) P F(2,48) P F(1,48) P 
%OAT 16.837 0.000 6.848 0.003 9.933 0.000 
%OAE 1.075 0.306 2.556 0.090 0.436 0.650 
Locomotion 0.105 0.748 0.938 0.399 1.836 0.172 
 





Figure 1: Open-arms exploratory behaviors following the pretest microinjections of NMDA, SKF, SKF prior to intra 
NAc shell injection of NMDA.After 24 h, all groups were retested in the EPM undrugged. %Open-Arms Time (A); 
%Open-Arms Entries (B) and Locomotor Activity (C).Values are expressed as mean±S.E.M (n = 8 in each 
group).*P<0.05, **P<0.01 and ***P<0.001 different from controlsaline group on test day. +P<0.05, ++P<0.01 and 
+++P<0.001 different from controlsaline groups on retest day. αP<0.05, ααP<0.01 and αααP<0.001 different from the 
test and retest group. ψP<0.05, ψψP<0.01 and ψψψP<0.001 different from the test groups. βP<0.05, ββP<0.01 and 
βββP<0.001 different from the retest groups. 
 






     In our study, animals were given pretest intra-
cerebral drugs injection, followed by no injection 
upon retest, 24 h later. Based on this; drug effects 
on anxiety-like behaviors and aversive learning 
with subsequent long-term effects on memory in 
24 h, were tested. It has been reported that the 
prior experience of an undrugged EPM testing 
session may alter the behavioral responses in an 
undrugged retest session [44, 45]. 
Our results indicated that the intra-NAc shell 
infusion of NMDA receptor agonist at applied 
doses induces an anxiolytic-like response in EPM. 
This NMDA- induced anxiolytic-like effect 
emerges into the retest day. Current findings 
suggest that NMDA treatment induces 
impairment in the aversive memory acquisition 
upon test. There is a body of evidence supporting 
that NAc shell is an essential brain site regulating 
emotion, motor activity [19], motivation-related 
learning, memory[20, 21] and anxiety-like 
behaviors [22-24]. On the other hand, the NMDA 
receptor (as an ionotropic glutamate receptor) 
plays a critical role in the regulation of glutamate-
induced behaviors such as learning and memory 
formation [4, 5] and anxiety-related behaviors [2, 
8].  
Some studies have displayed that glutamate 
retains an important role in anxiety and anxious 
behaviors and elicits its effect through different 
combinations of metabotropic and ionotropic 
glutamate receptors and potentially different 
subunit combinations [3, 46]. Our results are in 
agreement with the previous investigation 
showing that NMDA agonist releases behavioral 
and anxiolytic-like behaviors indicating the role 
of NMDA receptors in modulation of anxiety-
related behaviors [8, 46].Moreover, there is also 
an investigation showing that the activation of 
NMDA receptor induces anxiogenic-like effects 
in EPM and social interaction tasks [47].Based on 
some genetic insights, the NR2A subunit of the 
NMDA receptors involves in the anxiolytic-like 
responses seen in mice [48].The difference in 
anxiogenic/anxiolytic responses observed 
between studies can possibly be related to 
difference in endogenous glutamatergic tone 
under different laboratory settings [49]. These can 
partly be attributed to the doses of glutamatergic 
agents, the method used and the site(s) of drug 
administration. 
Evidence has suggested the critical role of NAc in 
regulation of several learning functions which 
require a flexible use of sensory information [50-
52]. It has been postulated that NAc 
manipulations induce spatial memory deficit in 
the Morris water-maze [52, 53] and radial maze 
[54, 55]. In agreement with our results, evidence 
has demonstrated that the systemic administration 
of NMDA leads to an impaired dark-avoidance 
learning in rats [56]. On the other hand, some 
investigations have postulated that the 
deactivation of the NAc glutamatergic ionotropic 
receptors disrupts the working memory[57-59] 
and spatial responses[60] while other 
contradictory studies have shown that the NMDA 
receptor blockade in NAc shell does not alter the 
spatial learning [51, 60].  
In addition our findings showed that, the intra-
NAc shell infusion of Ca
+2
 channel blocker SKF 
at applied doses, does not alter the anxiety-like 
response and aversive memory upon test and 
retest, respectively. Furthermore, infusing the 
subthreshold dose SKF prior to the injection of 
effective doses of NMDA, reduced the anxiolytic-
like response and improved the aversive memory 
impairment which had already been induced by 
intra-NAc shell NMDA injection. Our study 
showed that,inhibition of the neurotransmitter 
exocytosis from pre-synaptic neuron via Ca
+2
 
channel blockade bySKF96365 decreases 
anxiolytic-like behaviors induced by NMDA in 
the NAc shell region, indicating the involvement 
of the pre-synaptic NMDA receptors in NMDA 
induced responses.Therefore, NMDA's ability to 
increase anxiolytic-like behaviors and the 
aversive memory impairment may be the result of 
an action on pre-synaptic glutamatergic receptors 
which in turn decrease the glutamate effect at 










1. Collingridge, GL; Lester, RA. Excitatory amino 
acid receptors in the vertebrate central nervous 
system. Pharmacol Rev. 1989; 41(2): 143-210. 
2. Riaza Bermudo-Soriano, C; Perez-Rodriguez, 
MM; Vaquero-Lorenzo, C; Baca-Garcia, E. New 
perspectives in glutamate and anxiety. Pharmacol 
Biochem Behav. 2012; 100(4): 752-74. 
3. Bergink, V; van Megen, HJ; Westenberg, HG. 
Glutamate and anxiety. Eur 
Neuropsychopharmacol. 2004; 14(3): 175-83. 
4. Barkus, C; McHugh, SB; Sprengel, R; Seeburg, 
PH; Rawlins, JN; Bannerman, DM. Hippocampal 
NMDA receptors and anxiety: at the interface 
between cognition and emotion. Eur J Pharmacol. 
2010; 626(1): 49-56. 
5. Kew, JN; Kemp, JA. Ionotropic and 
metabotropic glutamate receptor structure and 
pharmacology. Psychopharmacology (Berl). 
2005; 179(1): 4-29. 
6. Cortese, BM; Phan, KL. The role of glutamate 
in anxiety and related disorders. CNS Spectr. 
2005; 10(10): 820-30. 
7. Vaquero-Lorenzo, C; Riaza Bermudo-Soriano, 
C; Perez-Rodriguez, MM; Diaz-Hernandez, M; 
Lopez-Castroman, J; Fernandez-Piqueras, J; Saiz-
Ruiz, Jet al. Positive association between SAT-1 -
1415T/C polymorphism and anxiety. Am J Med 
Genet B Neuropsychiatr Genet. 2009; 150B(4): 
515-9. 
8. Guimaraes, FS; Carobrez, AP; De Aguiar, JC; 
Graeff, FG. Anxiolytic effect in the elevated plus-
maze of the NMDA receptor antagonist AP7 
microinjected into the dorsal periaqueductal grey. 
Psychopharmacology (Berl). 1991; 103(1): 91-4. 
9. Storm-Mathisen, J; Leknes, AK; Bore, AT; 
Vaaland, JL; Edminson, P; Haug, FM; Ottersen, 
OP. First visualization of glutamate and GABA in 
neurones by immunocytochemistry. Nature. 1983; 
301(5900): 517-20. 
10. Riedel, G; Platt, B; Micheau, J. Glutamate 
receptor function in learning and memory. Behav 
Brain Res. 2003; 140(1-2): 1-47. 
11. MacDonald, JF; Nowak, LM. Mechanisms of 
blockade of excitatory amino acid receptor 
channels. Trends Pharmacol Sci. 1990; 11(4): 
167-72. 
12. Corlew, R; Brasier, DJ; Feldman, DE; Philpot, 
BD. Presynaptic NMDA receptors: newly 
appreciated roles in cortical synaptic function and 
plasticity. Neuroscientist. 2008; 14(6): 609-25. 
13. Duguid, I; Sjostrom, PJ. Novel presynaptic 
mechanisms for coincidence detection in synaptic 
plasticity. Curr Opin Neurobiol. 2006; 16(3): 312-
22. 
14. Lonchamp, E; Gambino, F; Dupont, JL; 
Doussau, F; Valera, A; Poulain, B; Bossu, JL. Pre 
and post synaptic NMDA effects targeting 
Purkinje cells in the mouse cerebellar cortex. 
PLoS One. 2012; 7(1): e30180. 
15. Kohr, G. NMDA receptor function: subunit 
composition versus spatial distribution. Cell 
Tissue Res. 2006; 326(2): 439-46. 
16. Yashiro, K; Philpot, BD. Regulation of 
NMDA receptor subunit expression and its 
implications for LTD, LTP, and metaplasticity. 
Neuropharmacology. 2008; 55(7): 1081-94. 
17. Catterall, WA; Few, AP. Calcium channel 
regulation and presynaptic plasticity. Neuron. 
2008; 59(6): 882-901. 
18. Zahm, DS. An integrative neuroanatomical 
perspective on some subcortical substrates of 
adaptive responding with emphasis on the nucleus 
accumbens. Neurosci Biobehav Rev. 2000; 24(1): 
85-105. 
19. da Cunha, IC; Lopes, AP; Steffens, SM; 
Ferraz, A; Vargas, JC; de Lima, TC; Marino Neto, 
Jet al. The microinjection of AMPA receptor 
antagonist into the accumbens shell, but not into 
the accumbens core, induces anxiolysis in an 
animal model of anxiety. Behav Brain Res. 2008; 
188(1): 91-9. 
20. Cardinal, RN; Everitt, BJ. Neural and 
psychological mechanisms underlying appetitive 
learning: links to drug addiction. Curr Opin 
Neurobiol. 2004; 14(2): 156-62. 
21. Huang, YH; Ishikawa, M; Lee, BR; 
Nakanishi, N; Schluter, OM; Dong, Y. Searching 
for presynaptic NMDA receptors in the nucleus 
accumbens. J Neurosci. 2011; 31(50): 18453-63. 
22. Plaznik, A; Palejko, W; Nazar, M; Jessa, M. 
Effects of antagonists at the NMDA receptor 
complex in two models of anxiety. Eur 
Neuropsychopharmacol. 1994; 4(4): 503-12. 
23. Martinez, G; Ropero, C; Funes, A; Flores, E; 
Landa, AI; Gargiulo, PA. AP-7 into the nucleus 
accumbens disrupts acquisition but does not affect 
consolidation in a passive avoidance task. Physiol 
Behav. 2002; 76(2): 205-12. 
 




24. Martinez, G; Ropero, C; Funes, A; Flores, E; 
Blotta, C; Landa, AI; Gargiulo, PA. Effects of 
selective NMDA and non-NMDA blockade in the 
nucleus accumbens on the plus-maze test. Physiol 
Behav. 2002; 76(2): 219-24. 
25. Brown, TE; Lee, BR; Mu, P; Ferguson, D; 
Dietz, D; Ohnishi, YN; Lin, Yet al. A silent 
synapse-based mechanism for cocaine-induced 
locomotor sensitization. J Neurosci. 2011; 31(22): 
8163-74. 
26. Berretta, N; Jones, RS. Tonic facilitation of 
glutamate release by presynaptic N-methyl-D-
aspartate autoreceptors in the entorhinal cortex. 
Neuroscience. 1996; 75(2): 339-44. 
27. Sjostrom, PJ; Turrigiano, GG; Nelson, SB. 
Neocortical LTD via coincident activation of 
presynaptic NMDA and cannabinoid receptors. 
Neuron. 2003; 39(4): 641-54. 
28. Bardoni, R; Torsney, C; Tong, CK; Prandini, 
M; MacDermott, AB. Presynaptic NMDA 
receptors modulate glutamate release from 
primary sensory neurons in rat spinal cord dorsal 
horn. J Neurosci. 2004; 24(11): 2774-81. 
29. Yang, J; Woodhall, GL; Jones, RS. Tonic 
facilitation of glutamate release by presynaptic 
NR2B-containing NMDA receptors is increased 
in the entorhinal cortex of chronically epileptic 
rats. J Neurosci. 2006; 26(2): 406-10. 
30. Corlew, R; Wang, Y; Ghermazien, H; Erisir, 
A; Philpot, BD. Developmental switch in the 
contribution of presynaptic and postsynaptic 
NMDA receptors to long-term depression. J 
Neurosci. 2007; 27(37): 9835-45. 
31. Brasier, DJ; Feldman, DE. Synapse-specific 
expression of functional presynaptic NMDA 
receptors in rat somatosensory cortex. J Neurosci. 
2008; 28(9): 2199-211. 
32. Larsen, RS; Corlew, RJ; Henson, MA; 
Roberts, AC; Mishina, M; Watanabe, M; Lipton, 
SAet al. NR3A-containing NMDARs promote 
neurotransmitter release and spike timing-
dependent plasticity. Nat Neurosci. 2011; 14(3): 
338-44. 
33. McGaugh, JL. The amygdala modulates the 
consolidation of memories of emotionally 
arousing experiences. Annu Rev Neurosci. 2004; 
27: 1-28. 
34. Asth, L; Lobao-Soares, B; Andre, E; Soares 
Vde, P; Gavioli, EC. The elevated T-maze task as 
an animal model to simultaneously investigate the 
effects of drugs on long-term memory and anxiety 
in mice. Brain Res Bull. 2012; 87(6): 526-33. 
35. Paxinos, G; Watson, C. The Rat Brain in 
Stereotaxic Coordinates (6rd ed.). Academic 
Press.London.UK. 2007. 
36. Carobrez, AP; Bertoglio, LJ. Ethological and 
temporal analyses of anxiety-like behavior: the 
elevated plus-maze model 20 years on. Neurosci 
Biobehav Rev. 2005; 29(8): 1193-205. 
37. Zarrindast, MR; Nasehi, M; Piri, M; Heidari, 
N. Effects of cholinergic system of dorsal 
hippocampus of rats on MK-801 induced 
anxiolytic-like behavior. Neurosci Lett. 2011; 
505(2): 65-70. 
38. Zarrindast, MR; Naghdi-Sedeh, N; Nasehi, M; 
Sahraei, H; Bahrami, F; Asadi, F. The effects of 
dopaminergic drugs in the ventral hippocampus of 
rats in the nicotine-induced anxiogenic-like 
response. Neurosci Lett. 2010; 475(3): 156-60. 
39. Nasehi, M; Mafi, F; Oryan, S; Nasri, S; 
Zarrindast, MR. The effects of dopaminergic 
drugs in the dorsal hippocampus of mice in the 
nicotine-induced anxiogenic-like response. 
Pharmacol Biochem Behav. 2011; 98(3): 468-73. 
40. Zarrindast, MR; Torabi, M; Rostami, P; Fazli-
Tabaei, S. The effects of histaminergic agents in 
the dorsal hippocampus of rats in the elevated 
plus-maze test of anxiety. Pharmacol Biochem 
Behav. 2006; 85(3): 500-6. 
41. Zarrindast, MR; Valizadegan, F; Rostami, P; 
Rezayof, A. Histaminergic system of the lateral 
septum in the modulation of anxiety-like 
behaviour in rats. Eur J Pharmacol. 2008; 583(1): 
108-14. 
42. Zarrindast, MR; Nasehi, M; Khansari, M; 
Bananej, M. Influence of nitric oxide agents in the 
rat amygdala on anxiogenic-like effect induced by 
histamine. Neurosci Lett. 2011; 489(1): 38-42. 
43. Zarrindast, MR; Solati, J; Oryan, S; Parivar, 
K. Effect of intra-amygdala injection of nicotine 
and GABA receptor agents on anxiety-like 
behaviour in rats. Pharmacology. 2008; 82(4): 
276-84. 
44. Stern, CA; Do Monte, FH; Gazarini, L; 
Carobrez, AP; Bertoglio, LJ. Activity in prelimbic 
cortex is required for adjusting the anxiety 
response level during the elevated plus-maze 
retest. Neuroscience. 2010; 170(1): 214-22. 
45. Carvalho, MC; Albrechet-Souza, L; Masson, 
S; Brandao, ML. Changes in the biogenic amine 
 




content of the prefrontal cortex, amygdala, dorsal 
hippocampus, and nucleus accumbens of rats 
submitted to single and repeated sessions of the 
elevated plus-maze test. Braz J Med Biol Res. 
2005; 38(12): 1857-66. 
46. Solati, J. Dorsal hippocampal N-methyl-D-
aspartate glutamatergic and delta-opioidergic 
systems modulate anxiety behaviors in rats in a 
noninteractive manner. Kaohsiung J Med Sci. 
2011; 27(11): 485-93. 
47. Dunn, RW; Corbett, R; Fielding, S. Effects of 
5-HT1A receptor agonists and NMDA receptor 
antagonists in the social interaction test and the 
elevated plus maze. Eur J Pharmacol. 1989; 
169(1): 1-10. 
48. Boyce-Rustay, JM; Holmes, A. Genetic 
inactivation of the NMDA receptor NR2A subunit 
has anxiolytic- and antidepressant-like effects in 
mice. Neuropsychopharmacology. 2006; 31(11): 
2405-14. 
49. Harvey, BH; Shahid, M. Metabotropic and 
ionotropic glutamate receptors as neurobiological 
targets in anxiety and stress-related disorders: 
focus on pharmacology and preclinical 
translational models. Pharmacol Biochem Behav. 
2012; 100(4): 775-800. 
50. Schacter, GB; Yang, CR; Innis, NK; 
Mogenson, GJ. The role of the hippocampal-
nucleus accumbens pathway in radial-arm maze 
performance. Brain Res. 1989; 494(2): 339-49. 
51. Maldonado-Irizarry, CS; Kelley, AE. 
Excitatory amino acid receptors within nucleus 
accumbens subregions differentially mediate 
spatial learning in the rat. Behav Pharmacol. 
1995; 6(5 And 6): 527-539. 
52. Sargolini, F; Florian, C; Oliverio, A; Mele, A; 
Roullet, P. Differential involvement of NMDA 
and AMPA receptors within the nucleus 
accumbens in consolidation of information 
necessary for place navigation and guidance 
strategy of mice. Learn Mem. 2003; 10(4): 285-
92. 
53. Setlow, B; McGaugh, JL. Sulpiride infused 
into the nucleus accumbens posttraining impairs 
memory of spatial water maze training. Behav 
Neurosci. 1998; 112(3): 603-10. 
54. Gal, G; Joel, D; Gusak, O; Feldon, J; Weiner, 
I. The effects of electrolytic lesion to the shell 
subterritory of the nucleus accumbens on delayed 
non-matching-to-sample and four-arm baited 
eight-arm radial-maze tasks. Behav Neurosci. 
1997; 111(1): 92-103. 
55. Smith-Roe, SL; Kelley, AE. Coincident 
activation of NMDA and dopamine D1 receptors 
within the nucleus accumbens core is required for 
appetitive instrumental learning. J Neurosci. 
2000; 20(20): 7737-42. 
56. Zajaczkowski, W; Frankiewicz, T; Parsons, 
CG; Danysz, W. Uncompetitive NMDA receptor 
antagonists attenuate NMDA-induced impairment 
of passive avoidance learning and LTP. 
Neuropharmacology. 1997; 36(7): 961-71. 
57. Klein, S; Hadamitzky, M; Koch, M; Schwabe, 
K. Role of glutamate receptors in nucleus 
accumbens core and shell in spatial behaviour of 
rats. Neuroscience. 2004; 128(2): 229-38. 
58. Baiardi, G; Ruiz, AM; Beling, A; Borgonovo, 
J; Martinez, G; Landa, AI; Sosa, MAet al. 
Glutamatergic ionotropic blockade within 
accumbens disrupts working memory and might 
alter the endocytic machinery in rat accumbens 
and prefrontal cortex. J Neural Transm. 2007; 
114(12): 1519-28. 
59. Jongen-Relo, AL; Kaufmann, S; Feldon, J. A 
differential involvement of the shell and core 
subterritories of the nucleus accumbens of rats in 
memory processes. Behav Neurosci. 2003; 
117(1): 150-68. 
60. Smith-Roe, SL; Sadeghian, K; Kelley, AE. 
Spatial learning and performance in the radial arm 
maze is impaired after N-methyl-D-aspartate 
(NMDA) receptor blockade in striatal subregions. 
Behav Neurosci. 1999; 113(4): 703-17. 
 
 
